Print this page
immunotherapy
-
Impact of Early Radiation Oncology Involvement as Part of a Multidisciplinary Palliative Care Team on Quality of Life Among Diverse Patients with Advanced/Metastatic Malignancies.
Protocol: 002168Principal Investigator:
-
Malcolm Mattes
Applicable Disease Sites: Any Site -
Fitness-Adapted, Pembrolizumab-Based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above.
Protocol: 012203Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma -
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.
Protocol: 012314Principal Investigator:
-
Joanna Rhodes
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 1 Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High/Very High Risk Myelodysplastic Syndrome (MDS).
Protocol: 022204Principal Investigator:
-
Dale Schaar
Applicable Disease Sites: Myeloid and Monocytic Leukemia
Other Hematopoietic -
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP- 5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Protocol: 022303Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/ Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia.
Protocol: 022305Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).
Protocol: 032002Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Lung -
A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm.
Protocol: 032006Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
The Role of Adaptive Radiation Planning in Patients with Non-Small Cell Lung Cancer on Radiation Induced Toxicity .
Protocol: 032009Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Lung -
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
A Prospective Randomized Study of Ramucirumab plus Pembrolizumab versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer.
Protocol: 032304Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Protocol: 032405Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer.
Protocol: 042012Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
Pilot Study to Investigate the Metabolic Pathways in Hormone Receptor-Positive/HER2-Negative Breast Cancer.
Protocol: 042210Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-Human Epidermal Growth Factor Receptor 2 (anti-HER2) Antibody-Drug Conjugate (ADC), in Previously Treated Subjects with HER2-Positive or HER2-Low Unresectable or Metastatic Breast Cancer.
Protocol: 042314Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast